A recent Phase II clinical trial involving patients with SLE demonstrated that Litifilimab (a humanized antibody against BDCA-2) could reduce cutaneous and joint involvement (LILAC ClinicalTrials.gov number NCT02847598) (139, 140). Here, CLEC4C is linked to systemic lupus erythematosus.